Overview

Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

Status:
Unknown status

Trial end date:
2018-11-01

Target enrollment:

Participant gender:

Summary

Asian patients with relapsed myeloma after prior treatment with bortezomib and lenalidomide will treatment on pomalidomde and dexamethasone. Baseline, follow-up, survival and toxicity information will be collected.

Phase:

Phase 2

Details

Lead Sponsor:

National University Hospital, Singapore

Collaborator:

Celgene

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Pomalidomide
Thalidomide